Guardian Wealth Management Inc. Grows Position in Johnson & Johnson (NYSE:JNJ)

Guardian Wealth Management Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,985 shares of the company’s stock after acquiring an additional 226 shares during the period. Johnson & Johnson makes up approximately 1.5% of Guardian Wealth Management Inc.’s holdings, making the stock its 26th biggest holding. Guardian Wealth Management Inc.’s holdings in Johnson & Johnson were worth $2,104,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Occidental Asset Management LLC grew its position in Johnson & Johnson by 21.6% in the second quarter. Occidental Asset Management LLC now owns 3,416 shares of the company’s stock worth $499,000 after acquiring an additional 607 shares in the last quarter. Bangor Savings Bank boosted its holdings in shares of Johnson & Johnson by 3.0% in the 2nd quarter. Bangor Savings Bank now owns 26,933 shares of the company’s stock worth $3,936,000 after purchasing an additional 776 shares during the period. Voisard Asset Management Group Inc. increased its position in shares of Johnson & Johnson by 93.2% during the 2nd quarter. Voisard Asset Management Group Inc. now owns 1,244 shares of the company’s stock valued at $182,000 after purchasing an additional 600 shares during the last quarter. JFS Wealth Advisors LLC raised its holdings in Johnson & Johnson by 29.6% during the 2nd quarter. JFS Wealth Advisors LLC now owns 20,461 shares of the company’s stock valued at $2,991,000 after buying an additional 4,671 shares during the period. Finally, Brendel Financial Advisors LLC bought a new stake in Johnson & Johnson in the second quarter worth $857,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $149.31 on Monday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock’s fifty day moving average price is $158.09 and its 200-day moving average price is $156.40. The firm has a market cap of $359.48 billion, a P/E ratio of 21.61, a P/E/G ratio of 2.65 and a beta of 0.51. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the previous year, the business posted $2.66 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Citigroup increased their price objective on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, Guggenheim boosted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $175.67.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.